{"id":"susoctocog-alfa","rwe":[],"tags":[{"label":"Biologic","category":"modality"},{"label":"B02BD14","category":"atc"},{"label":"Active","category":"status"},{"label":"Acquired factor VIII deficiency disease","category":"indication"},{"label":"Baxalta Innovations GmbH","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Baxalta Innovations GmbH","patents":[{"type":"Biologic Exclusivity","filed":"October 23, 2014","source":"FDA Purple Book","status":"Active","expires":"October 23, 2021","territory":"US","patentNumber":"BLA 125512"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SUSOCTOCOG ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:07:32.659324+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T02:07:32.659212+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:07:39.030970+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T02:07:32.727028+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SUSOCTOCOG ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:07:39.329400+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor VIII exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:07:40.627337+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5315075/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:07:40.276407+00:00"}},"allNames":"obizur","offLabel":[],"synonyms":["susoctocog alfa","obizur"],"timeline":[{"date":"2015-11-11","type":"positive","source":"DrugCentral","milestone":"EMA approval (Baxalta Innovations GmbH)"}],"approvals":[{"date":"2015-11-11","orphan":false,"company":"Baxalta Innovations GmbH","regulator":"EMA"}],"brandName":"Obizur","ecosystem":[{"indication":"Acquired factor VIII deficiency disease","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Obizur is a small molecule that acts as a replacement or supplement for the deficient factor VIII protein, which is essential for the intrinsic pathway of blood coagulation. By replenishing or augmenting factor VIII activity, Obizur helps to restore normal hemostasis and prevent bleeding complications in patients with acquired factor VIII deficiency disease."},"commercial":{},"purpleBook":{"bla":"125512","source":"FDA Purple Book","approvalDate":"October 23, 2014","licenseStatus":"Licensed","exclusivityExpiry":"October 23, 2021"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5069","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SUSOCTOCOG%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SUSOCTOCOG ALFA","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://purplebooksearch.fda.gov/","fields":["biologicExclusivity"],"source":"FDA Purple Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:47:00.129881","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:07:41.842075+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"vonicog alfa","drugSlug":"vonicog-alfa","fdaApproval":"2015-12-08","relationship":"same-class"}],"genericName":"susoctocog alfa","indications":{"approved":[{"name":"Acquired factor VIII deficiency disease","source":"DrugCentral","snomedId":14230004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"vonicog-alfa","brandName":"vonicog alfa","genericName":"vonicog alfa","approvalYear":"2015","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06461533","phase":"","title":"A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-06-10","conditions":["Acquired Hemophilia A"],"enrollment":25,"completionDate":"2029-10-31"}],"_emaApprovals":[{"date":"2015-11-11","status":"Authorised","company":"Baxalta Innovations GmbH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"233325","NDDF":"002035","UNII":"6892UQT2GK","VANDF":"4019616","INN_ID":"9822","RXNORM":"1592899","UMLSCUI":"C3859426","chemblId":"CHEMBL5315075","DRUGBANK_ID":"DB11606","PUBCHEM_CID":"104815","SNOMEDCT_US":"278910002"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Baxalta Innovations GmbH","relationship":"Original Developer"}],"publicationCount":23,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"B02BD14","allCodes":["B02BD14"]},"biosimilarFilings":[],"originalDeveloper":"Baxalta Innovations GmbH","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Baxalta Innovations GmbH","companyId":"baxalta-innovations-gmbh","modality":"Recombinant protein","firstApprovalDate":"2015","aiSummary":"Obizur is an exogenous protein used to treat hemophilia A, and it works by replacing the coagulation factor VIII. It is administered to patients with severe hemophilia A.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2015-11-11T00:00:00.000Z","mah":"Baxalta Innovations GmbH","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:07:41.842075+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}